Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK -positive non-small-cell lung cancer-Reference-Cited by-同舟云学术

Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK -positive non-small-cell lung cancer

Published:2018-07 Issue: Volume:121 Page:37-40
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Nishio Makoto,Nakagawa Kazuhiko,Mitsudomi Tetsuya,Yamamoto Nobuyuki,Tanaka Tomohiro,Kuriki Hiroshi,Zeaiter Ali,Tamura Tomohide

Funder

Chugai Pharmaceutical Co. Ltd.

Astellas Pharma

Bristol-Myers Squibb Japan

Eli Lilly

Merck Sharp & Dohme

Novartis

Ono Pharmaceutical Co. Ltd.

Pfizer

Taiho Pharmaceutical Co. Ltd

AbbVie Inc.

AC MEDICAL Inc.

AstraZeneca

Bristol-Myers Squibb

Covance

Daiichi Sankyo Co. Ltd.

Eisai

Eli Lilly Japan

EPS International

GlaxoSmithKline

Kyowa Hakko Kirin Co. Ltd.

Merck Serono

Nippon Boehringer Ingelheim Co. Ltd.

Otsuka Pharmaceutical Co. Ltd

PAREXEL International

Pfizer Japan

Quintiles

Taiho Pharmaceutical Co. Ltd.

Yakult Honsha Co. Ltd.

F. Hoffmann-La Roche Ltd

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference10 articles.

1. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases;Costa;J. Clin. Oncol.,2015

2. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar;Tang;Int. J. Cancer,2014

3. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study;Gadgeel;Lancet Oncol.,2014

4. Three-year follow-up of an alectinib phase I/II study in ALK-positive non-small-cell lung cancer: AF-001JP;Tamura;J. Clin. Oncol.,2017

5. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study;Ou;J. Clin. Oncol.,2016

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study;JTO Clinical and Research Reports;2024-09

2. Alectinib vs. Lorlatinib in the Front-Line Setting for ALK-Rearranged Non-Small-Cell Lung Cancer (NSCLC): A Deep Dive into the Main Differences across ALEX and CROWN Phase 3 Trials;Cancers;2024-07-04

3. A Review of the Molecular Determinants of Therapeutic Response in Non-Small Cell Lung Cancer Brain Metastases;International Journal of Molecular Sciences;2024-06-26

4. First-Line Alectinib vs. Brigatinib in Advanced Non–Small Cell Lung Cancer with ALK Rearrangement: Real-World Data;Cancer Research and Treatment;2024-01-15

5. Comparative analysis of combined treatment methods for patients with single brain lesions;Burdenko's Journal of Neurosurgery;2024